• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

ACOs Edging Toward Downside Risk

Publication
Article
MHE PublicationMHE November 2020
Volume 30
Issue 11

The Trump administration’s push to get more Medicare Shared Savings Program (MSSP) ACOs to take on downside risk is having an effect, but there are still many nontakers.

The Trump administration’s push to get more Medicare Shared Savings Program (MSSP) ACOs to take on downside risk is having an effect, but there are still many nontakers.

According to tallies in an analysis published on the Health Affairs blog last month, 53% of the 139 MSSP ACOs that migrated out of the regular MSSP program last year into the administration’s Pathways to Success program took on downside risk. That makes sense because the Pathways program is designed to encourage ACOs to take on downside risk. But a greater proportion (309 out of 514, or 60%) of the MSSP ACOs stayed in the legacy program and only 17% of those ACOs took on downside risk.

Trump administration health officials — and a number of experts outside the administration — have argued that the ACOs will realize their value-base care potential only if they take on downside risk, the shorthand way of saying that penalties would be assessed if the ACO exceeds financial benchmarks.

The analysis was conducted by Mark McClellan, M.D., Ph.D., director the Duke-Margolis Center for Health Policy at Duke University, and his colleagues.

McClellan, who was FDA commissioner and CMS administrator during the George W. Bush administration, and his co-authors say cost and quality metrics for ACOs this year will be “muddled” because of the COVID-19 pandemic and uncertainty about the effects of the adjustments CMS has made in the program. They note, though, that the dire scenario of an exodus of ACOs because of the Pathway of Success rules didn’t happen last year

Related Videos
Video 6 - "Navigating Insurance Coverage for Prescription Digital Therapeutics"
Video 5 - "FDA Approval Pathway for Prescription Digital Therapeutics"
Video 8 - "Gaps in Evidence Generation for Digital Therapeutics"
Video 7 - "Adoption Lessons For Payers"
Video 10 - "Managing Self Care"
Video 3 - "Embracing and Improving Access to Technology Tools"
Video 4 - "Assessing the Cost-Effectiveness of Prescription Digital Therapeutics "
© 2024 MJH Life Sciences

All rights reserved.